Prognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung cancer surgery

dc.contributor.authorRamos Izquierdo, Ricard
dc.contributor.authorMacía, Ivan
dc.contributor.authorNavarro Martín, Arturo
dc.contributor.authorDéniz, Carlos
dc.contributor.authorRivas, Francisco
dc.contributor.authorUreña Lluveras, Anna
dc.contributor.authorMasuet Aumatell, Cristina
dc.contributor.authorMoreno, Camilo
dc.contributor.authorNadal, Ernest
dc.contributor.authorEscobar Campuzano, Ignacio
dc.date.accessioned2021-04-20T15:29:44Z
dc.date.available2021-04-20T15:29:44Z
dc.date.issued2021-03-02
dc.date.updated2021-04-20T15:29:44Z
dc.description.abstractBackground: Tthe aim of this study was to assess the effect of the lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on overall survival and disease-free survival in patients with lung cancer treated with radical surgery. Methods: we performed a retrospective review of patients with lung cancer who prospectively underwent radical resection between 2004 and 2012. Blood samples were taken as part of the preoperative workup. The inflammatory markers studied were absolute values of lymphocytes, monocytes, neutrophils and platelets, with subsequent calculation of ratios. Median follow-up was 52 months. Results: two hundred and sixty-eight patients underwent surgery, of whom 218 (81.3%) were men. Mean age was 62.9 ± 8.7 years. A lymphocyte-to-monocyte ratio ≥ 2.5 was independently associated with longer disease-free survival (hazard ratio [HR] 0.476 (0.307-0.738), p = 0.001) and longer overall survival (HR, 0.546; 95% CI: 0.352-0.846; p = 0.007), in models adjusted for age, sex, stage, and type of resection. No other systemic inflammatory marker showed a significant association. Conclusion: preoperative LMR is an independent prognostic factor of overall survival and recurrence-free survival in patients with surgically-resected early stage lung cancer.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec711051
dc.identifier.issn1471-2466
dc.identifier.pmid33653309
dc.identifier.urihttps://hdl.handle.net/2445/176526
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s12890-021-01446-1
dc.relation.ispartofBMC Pulmonary Medicine, 2021, vol. 21, num. 1, p. 75
dc.relation.urihttps://doi.org/10.1186/s12890-021-01446-1
dc.rightscc-by (c) Ramos Izquierdo, Ricard et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationCàncer de pulmó
dc.subject.classificationSang
dc.subject.classificationLimfòcits
dc.subject.otherLung cancer
dc.subject.otherBlood
dc.subject.otherLymphocytes
dc.titlePrognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung cancer surgery
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
711051.pdf
Mida:
1.03 MB
Format:
Adobe Portable Document Format